Please login to the form below

Not currently logged in
Email:
Password:

Bavarian Nordic and Acambis settle legal dispute

Bavarian Nordic and Acambis reach an out-of-court global settlement over legal disputes regarding smallpox vaccines based on the Modified Vaccinia Ankara virus

Danish vaccine developer Bavarian Nordic and UK-based Acambis have reached an out-of-court global settlement over legal disputes regarding smallpox vaccines based on the Modified Vaccinia Ankara (MVA) virus.

Under the settlement Bavarian Nordic will grant a license to some of its MVA patents in return for Acambis making an undisclosed upfront payment.

Acambis will also make royalty and milestones payments should it develop or commercialise certain MVA products in the future.

The settlement involves the patent disputes at the U.S. International Trade Commission (ITC) and the Commercial Court in Vienna, Austria, as well as the conversion, unfair trade acts and unfair competition action at the US Federal District Court of the District of Delaware.

The terms of the out-of-court settlement are confidential, and there will be no further litigation or appeals. The financial guidance for both Bavarian Nordic and Acambis remain unchanged.

"This settlement brings to an end the litigation between our two companies and provides a basis for both companies to progress their respective vaccine businesses unhindered by these legal disputes," said Peter Wuff, president and CEO of Bavarian Nordic, and Ian Garland, CEO of Acambis in a joint statement.

In September 2006, an administrative judge at the International Trade Commission (ITC) ruled that two patents related to Bavarian's MVA vaccine were infringed but valid. The ITC in February sent the case back to the judge, with a new decision due in November.

The two companies will now submit a joint motion to the ITC for the termination of that investigation.

26th July 2007

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

DEMAND DIVERSITY REPORT 02: Why is the LGBTQ+ community facing poorer health outcomes due to COVID-19?
We’re all aware that clinical trials have been discussed more widely since the COVID-19 pandemic. While that’s a great thing for raising awareness of clinical trials in general, it’s also...
CHECKLIST 04: Let’s make your patient recruitment strategies a success
From how to generate insights to define your audience to drilling down those all-important key messages, our checklist has everything you need to think of, covered....
Multichannel engagement and the need for greater understanding of European markets
By Laurence Olding and Georgina James...

Infographics